The partnership will see the creation of custom products that combine KD Nutra’s KD-PüR high concentrate omega-3s with NattoPharma’s Vitamin K2 named MenaQ7 PharmaPure MK-7.
NattoPharma will market the new products, part of the K2ardio3 Platform, offering a variety of custom formulations including complementary CV ingredients such as plant sterols.
Omega-3s are widely known and accepted for their cardiovascular benefits, and KD-Nutra claims its technology gently extracts and purifies Omega-3s without the use of excessive heat, chemical solvents or oxygen.
NattoPharma says its MenaQ7 PharmaPure MK-7: MenaQ7 will provide the missing piece of the cardiovascular puzzle as it is the only vitamin K2 clinically proven to provide benefits for heart health, including maintaining and promoting arterial flexibility.
Vitamin K2 awareness
NattoPharma argues that widespread Vitamin K deficiency has had an indelible impact on global cardiovascular and bone health, yet there is no established specific RDI for Vitamin K2.
The firm announced its intention to spearhead the pursuit of a K2-specific RDI in 2018 and a number of studies have been published in recent months stating the importance of differentiating between the two.
Nutrients has recently published a new review paper clearly identifying differences between Vitamins K1 and K2.
NutraIngredients also recently reported on a Norweigan study which concluded that vitamin K2 provides heart health benefits, but not K1.